AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03720795 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stepped Care CBT
Description: Stepped Care CBT is a multi-method, parent-led approach, consisting of two main steps. Step one involves a low-intensity delivery of CBT, consisting of more flexible, parent-led, at-home treatment. Participants who do not show improvement in symptom severity at the end of Step One, are then stepped up to receive Step Two. Step two involves a high intensity delivery of CBT, consisting of therapist-led, parent-assisted weekly treatment sessions.
Study NCT04185298 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mSIM intervention plus activity monitoring
Description: Participants will receive the full mSIM intervention and be monitored (via Fitbit)
Study NCT04185298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity monitoring
Description: Participants will have activity monitored (via Fitbit)
Study NCT03504488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAB-ROR2-ADC
Description: Conditionally active biologic anti-ROR2 antibody drug conjugate
Study NCT03504488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: PD-1 inhibitor
Study NCT03936959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3434172
Description: Administered IV
Study NCT04183322 — intervention group
Intervention type: BIOLOGICAL
Intervention: 13-valent pneumococcal conjugate vaccine
Study NCT04479813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine 0.2 MG
Description: Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
Study NCT04479813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will be allocated to undergo conditioning or non conditioning assigned in a randomized order. Participants will be given placebo or 0.2mg of Moxonidine to take orally 20 minutes prior to the first endothelial function measurement.
Study NCT03330665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Meditate 3 times a week using headspace app
Study NCT00099437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: intramuscular injection
Study NCT03835377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron-biofortified beans
Description: Iron-biofortified beans (Phaseolus vulgaris L MIB465)
Study NCT03835377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control beans
Description: Control beans (Phaseolus vulgaris L Jamapa variety), identical in color and size
Study NCT02910622 — intervention group
Intervention type: OTHER
Intervention: Chimio-oncogramme
Description: Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
Study NCT04061967 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sending of screening summon.
Description: 2019-2021 - A Cobas PCR Female swab sample packet will be sent. Response rates (participation) will be measured.~2022 and onwards - A FLOQSwab and corresponding sample tube for analysis on the BD COR platform will be sent.
Study NCT02468024 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lung Surgery
Description: Sublobar Lung Resection
Study NCT02468024 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Stereotactic Ablative Radiotherapy, 54 Gy in 3 fractions
Study NCT04384692 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT04384692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT02288247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral
Study NCT02288247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: intravenous infusion
Study NCT04384692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study NCT04384692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT04384692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02288247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: intravenous infusion
Study NCT02288247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Oral
Study NCT03764059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtek™ Bulk Fill Posterior Restorative
Description: The subjects were assigned to either the investigational device (Filtek™ Bulk Fill Posterior Restorative) or the control device (Filtek™ Z350XT Universal Restorative) per web-based randomization system.
Study NCT03764059 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filtek™ Z350XT Universal Restorative
Description: The subjects were assigned to either the investigational device (Filtek™ Bulk Fill Posterior Restorative) or the control device (Filtek™ Z350XT Universal Restorative) per web-based randomization system.
Study NCT02619071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor sampling
Description: Bone marrow aspirate, blood sampling
Study NCT02619071 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Constiutional DNA sampling
Description: Buccal swab or Hair follicles
Study NCT02309918 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LDV/SOF FDC
Description: Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily
Study NCT04503252 — intervention group
Intervention type: OTHER
Intervention: Blood samples for the measurement of the concentration of cefazolin
Description: Blood samples for the measurement of the concentration of cefazolin will be collected on the 1st (mid-dose and trough sample), 3rd (mid-dose and trough sample),7th and 14th day (for both only trough sample) of cefazolin treatment (+/-1-5 day) and if applicable in weekly intervals during outpatient parenteral antibiotic treatment (usually within 4 weeks after inclusion; only in patients on outpatient continuous parenteral antibiotic treatment).
Study NCT04503252 — intervention group
Intervention type: OTHER
Intervention: S. aureus culture isolate
Description: The S. aureus culture isolate will be subjected to exact cefazolin MIC determination and to measurement of the level of cefazolin tolerance.
Study NCT04503252 — intervention group
Intervention type: OTHER
Intervention: structured telephone interview
Description: Structured telephone interview for Patient follow- up after 30 days
Study NCT04503252 — intervention group
Intervention type: OTHER
Intervention: Sub-study quantitative measurement of Torque Teno virus
Description: An additional EDTA sample will be drawn for quantitative polymerase chain reaction (PCR) of TTV DNA and analyses of cytokines and other parameters of the activation state of the immune system.
Study NCT04503252 — intervention group
Intervention type: OTHER
Intervention: Sub-study investigating cefazolin concentrations in sweat
Description: For each visit of included patients, a sweat sample will be collected via a CE certified Macroduct Sweat Collector. Eccrine sweat glands of the lower forearms are stimulated by pilocarpine (a parasympathomimetic) as well as a local current for 5min. Sweat is subsequently collected by capillary containers during 30min and transferred to small tubes on dry ice. Sweat sample analysis is conducted using mass spectrometry.
Study NCT00922792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII, long acting
Description: Single dose of 0,2 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration
Study NCT00922792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII, long acting
Description: Multiple doses of 100 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration every 48 hours
Study NCT02720315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensive cryotherapy
Description: Application of ice inside a plastic bag wrapped to the patient's site of pain, and held in place for 20min.
Study NCT02544061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NM-IL-12
Description: single 12 µg unit subcutaneous (SC) dose of NM-IL-12
Study NCT02544061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single subcutaneous dose
Study NCT04078230 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extend LymphAdenectomy
Description: Expanded lymph node dissection for right liver tumors included stations 12, 8, and 13, and stations 12, 1, 3, 7, and 8 for left liver tumors
Study NCT00168337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
Study NCT00168337 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham posterior segment drug delivery system-needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
Study NCT03309410 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Venous to arterial conversion (v-TAC)
Description: This was an observational study. Paired arterial blood gas and venous blood gas was drawn from each patient and compared. Venous blood gas was converted to arterial blood gas values using v-TAC.
Study NCT00628394 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atomoxetine
Description: 40mg 2po qam
Study NCT00628394 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: 40mg 2po qam
Study NCT02687477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Arterial Denervation
Description: Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
Study NCT02687477 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: patient in the sham group will receive sham procedure
Study NCT04155788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Exposure
Description: Participants will complete a meal exposure using one of their feared foods.
Study NCT02309554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SILCS diaphragm used with ContraGel
Description: SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. ContraGel is a clear, water soluble greaseless gel packed in a metal tube.
Study NCT02309554 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SILCS diaphragm used with 3% Nonoxynol-9
Description: SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. 3% Nonoxynol-9 (branded as Gynol II) is clear, unscented water soluble greaseless gel packed in plastic tubes with a vaginal applicator.
Study NCT02309554 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SILCS diaphragm
Description: SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring
Study NCT02835625 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic Mammography + Digital Breast Tomosynthesis
Description: Two-view tomosynthesis performed with GE Senoclaire 3D Breast Tomosynthesis.
Study NCT02309554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SILCS diaphragm
Description: SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring
Study NCT02912013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Me Mini
Description: Home use hair removal device
Study NCT03406689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac 0.1% Oph Susp
Description: One drop of Nepafenac 0.1% will be instilled 45' prior to the IVI.
Study NCT03406689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac 0.3% Oph Susp
Description: One drop of Nepafenac 0.3% will be instilled 45' prior to the IVI.
Study NCT03406689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tear
Description: One drop Artificial Tears will be instilled 45' prior to the IVI.
Study NCT02835625 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Digital mammography
Description: Two-view digital mammography performed with GE Senoclaire 3D Breast Tomosynthesis.
Study NCT01925729 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ragweed
Description: ragweed arm only
Study NCT01925729 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: histamine
Description: histamine arm only
Study NCT01925729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pseudoephedrine
Description: pseudoephedrine arm only
Study NCT01925729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline
Description: oxymetazoline arm only
Study NCT02641093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered one week prior to surgery and then every three weeks in the adjuvant setting for a total of 7 doses.
Study NCT02288247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Oral
Study NCT02288247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT02641093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: gross total surgical resection
Study NCT04454788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Genetically modified tissue plasminogen activator at a dose of 0.25mg/kg given as intravenous bolus over 5-10 seconds
Study NCT04384692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound imaging
Study NCT03924193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine Dimesylate
Description: Participants randomly assigned to this arm will receive 12 weeks of LDX medication.
Study NCT03924193 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy
Description: Participants randomly assigned to this arm will receive 12 weeks of Cognitive-Behavioral Therapy
Study NCT03924193 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combination LDX and Cognitive-Behavioral Therapy
Description: Participants randomly assigned to this arm will receive 12 weeks of LDX and Cognitive-Behavioral Therapy
Study NCT03355378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gum chewing
Description: chewing gum orally for 30 minutes
Study NCT01936168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanochemical Endovenous Ablation (MOCA)
Description: Mechanochemical Endovenous Ablation (MOCA)for treatment of great saphenous vein incompetence
Study NCT01936168 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Description: Radiofrequency ablation (RFA)for treatment of great saphenous vein incompetence
Study NCT01777685 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sulpiride
Study NCT04454788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care (which may include intravenous Alteplase)
Description: Patients will receive standard care which may include intravenous alteplase at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
Study NCT03573700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03573700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT03573700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV
Study NCT03573700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest.
Study NCT03573700 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19- specific CAR engineered autologous T-cells (SJCAR19 product)
Description: Given IV
Study NCT00933231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Standard dose, Oral
Study NCT00933231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Low dose, Oral
Study NCT00933231 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Simulect
Description: IV
Study NCT00933231 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Simulect
Description: IV
Study NCT00933231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cellcept
Description: Oral
Study NCT00933231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cellcept
Description: Oral
Study NCT00933231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: IV and Oral
Study NCT00933231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: IV and Oral
Study NCT00933231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Oral
Study NCT00933231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Oral
Study NCT00933231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Oral
Study NCT00933231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Oral
Study NCT03133546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Osimertinib is administered orally at 80mg once daily. Doses should be taken approximately 24 hours apart at the same time point each day. The appropriate number of osimertinib tablets will be provided to patients to be self-administered at home. AstraZeneca will supply osimertinib as tablets for oral administration.~AstraZeneca will supply osimertinib as tablets for oral administration.
Study NCT03133546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib is administered orally at 80mg once daily. Doses should be taken approximately 24 hours apart at the same time point each day. The appropriate number of osimertinib tablets will be provided to patients to be self-administered at home. AstraZeneca will supply osimertinib as tablets for oral administration.~AstraZeneca will supply osimertinib as tablets for oral administration.
Study NCT03133546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is administered at 15mg/kg intravenously on day 1 of every 3-week cycle. Bevacizumab for intravenous administration will be supplied by Roche.
Study NCT04440982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM015
Description: LUM015 will be administered 2 to 6 hours prior to surgery for both arms. The LUM Imaging device will be used to assist in the removal of additional tumor tissue in the device intervention arm.
Study NCT04440982 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LUM015
Description: LUM015 will be administered 2 to 6 hours prior to surgery for both arms. The LUM Imaging device will be used to assist in the removal of additional tumor tissue in the device intervention arm.
Study NCT04440982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lum Imaging System
Description: UM015 will be administered 2 to 6 hours prior to surgery for both arms. The LUM Imaging device will be used to assist in the removal of additional tumor tissue in the device intervention arm.
Study NCT02921997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 oil-in-water emulsion adjuvant.
Study NCT02921997 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203
Description: Inactivated monovalent subvirion H3N2v vaccine containing hemagglutinin (HA) of A/Minnesota/11/2010 NYMC X-203 virus.